Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan’s Generic Advair Delay Gives Leverage To Rivals

Executive Summary

Mylan received a “complete response” letter from FDA on its application for a generic version of GSK’s blockbuster Advair, offering scarce details on the reason why or possible length of the delay.

Advertisement

Related Content

Generic Manufacturers Try To Up Their Game As US Pressure Persists
Advair Generic: Mylan Takes Issue With US FDA's 'Major' Concerns
Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals
Mylan’s EpiPen Recall: Another Hit On The Auto-Injector
Mylan’s EpiPen Recall: Adding Insult To An Injured Product
Keeping Track: US FDA Approvals Binge Continues With Dupixent, Ocrevus And Zejula; Two CAR-T Are Under Review
Advair Generic Approval Uncertain Despite US FDA Denial Of Sandoz Petition
Mylan Plans Summer Launch For Advair Generic, Now Called Wixela Inhub
Teva AirDuo Poised To Be A Discounted, But Not Interchangeable, Version Of Advair

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120342

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel